Immune minimization strategies in renal transplantation

Immunological Investigations

Volumn 43, Issue 8, 2014, Pages 807-818

  Brar, Jyoti Eknoor ^a   Nader, Nader D ^b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c VAWestern NY Healthcare System Anesthesiology Services   (United States)

Author keywords

Calcineurin inhibitors; Corticosteroids; Minimization; Transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; ALLOANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ANTIBODY MEDIATED REJECTION; DRUG MECHANISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; GRAFT REJECTION; IMMUNOLOGY; METABOLISM; PERSONALIZED MEDICINE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; CALCINEURIN INHIBITORS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALIZED MEDICINE; ISOANTIBODIES; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84911020115     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2014.937492     Document Type: Review

References (38)

1. Abbas AK. (2011). Cellular and Molecular Immunology. Philadelphia: Saunders/Elsevier.
2. Abramowicz D, Del Carmen Rial M, Vitko S, et al. (2005). Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol, 16, 2234-40.
3. Ahsan N, Hricik D, Matas A, et al. (1999). Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study. Steroid Withdrawal Study Group. Transplantation, 68, 1865-74.
4. Almawi WY, Melemedjian OK, Rieder MJ. (1999). An alternate mechanism of glucocorticoid anti-proliferative effect: Promotion of a Th2 cytokine-secreting profile. Clin Transplant, 13, 365-74.
5. Cibrik D, Silva Jr. HT,, Vathsala A, et al. (2013). Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation, 95, 933-42.
6. Citterio F. (2001). Steroid side effects and their impact on transplantation outcome. Transplantation, 72, S75-80.
7. DeVos JM, Gaber AO, Knight RJ, et al. (2012). Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int, 82, 598-604.
8. Dudley C, Pohanka E, Riad H, et al. (2005). Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation, 79, 466-75.
9. Ekberg H, Grinyo J, Nashan B, et al. (2007a). Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant, 7, 560-70.
10. Ekberg H, Tedesco-Silva H, Demirbas A, et al. (2007b). Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med, 357, 2562-75.
11. Everly MJ, Everly JJ, Arend LJ, et al. (2009). Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant, 9, 1063-71.
12. Frimat L, Cassuto-Viguier E, Charpentier B, et al. (2006). Impact of cyclosporine reduction with MMF: A randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant, 6, 2725-34.
13. Gaston RS, Cecka JM, Kasiske BL, et al. (2010). Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation, 90, 68-74.
14. Humar A, Gillingham K, Kandaswamy R, et al. (2007). Steroid avoidance regimens: A comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transplant, 7, 1948-53.
15. Jardine AG. (2005). Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int, 18, 379-84.
16. Johnson RW, Kreis H, Oberbauer R, et al. (2001). Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation, 72, 777-86.
17. Laftavi MR, Stephan R, Stefanick B, et al. (2005). Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery, 137, 364-71.
18. Larson TS, Dean PG, Stegall MD, et al. (2006). Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant, 6, 514-22.
19. Matas AJ. (2009). Minimization of steroids in kidney transplantation. Transpl Int, 22, 38-48.
20. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. (2004). Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant, 4, 378-83.
21. Nankivell BJ, Borrows RJ, Fung CL, et al. (2004). Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation, 78, 557-65.
22. Oberbauer R, Segoloni G, Campistol JM, et al. (2005). Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int, 18, 22-8.
23. Ojo AO, Held PJ, Port FK, et al. (2003). Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med, 349, 931-40.
24. Pascual J, Royuela A, Galeano C, et al. (2012). Very early steroid withdrawal or complete avoidance for kidney transplant recipients: A systematic review. Nephrol Dial Transplant, 27, 825-32.
25. Prasad GV, Nash MM, McFarlane PA, Zaltzman JS. (2003). Renal transplant recipient attitudes toward steroid use and steroid withdrawal. Clin Transplant, 17, 135-9.
26. Rostaing L, Vincenti F, Grinyo J, et al. (2013). Long-term belatacept exposure maintains efficacy and safety at 5 years: Results from the long-term extension of the BENEFIT study. Am J Transplant, 13, 2875-83.
27. Rostaing L, Cantarovich D, Mourad G, et al. (2005). Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation, 79, 807-14.
28. Schena FP, Pascoe MD, Alberu J, et al. (2009). Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation, 87, 233-42.
29. Sellares J, de Freitas DG, Mengel M, et al. (2012). Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant, 12, 388-99.
30. Sinclair NR. (1992). Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ, 147, 645-57.
31. Snanoudj R, Royal V, Elie C, et al. (2011). Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant, 11, 2635-46.
32. Vanrenterghem Y, Lebranchu Y, Hene R, et al. (2000). Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation, 70, 1352-9.
33. Veenstra DL, Best JH, Hornberger J, et al. (1999). Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis, 33, 829-39.
34. Vincenti F, Schena FP, Paraskevas S, et al. (2008). A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant, 8, 307-16.
35. Weir MR, Mulgaonkar S, Chan L, et al. (2011). Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial. Kidney Int, 79, 897-907.
36. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. (2012). Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant, 12, 1157-67.
37. Wolfe RA, Ashby VB, Milford EL, et al. (1999). Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med, 341, 1725-30.
38. Woodle ES, First MR, Pirsch J, et al. (2008). A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg, 248, 564-77.